Difference between revisions of "Toripalimab (Loqtorzi)"
Jump to navigation
Jump to search
m (→Also known as) |
m |
||
| Line 10: | Line 10: | ||
*[[Non-small cell lung cancer, squamous]] | *[[Non-small cell lung cancer, squamous]] | ||
| + | ==History of changes in NMPA indication== | ||
| + | *2018-12-17: Initial approval | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' | + | *'''Code names:''' JS-001, TAB-001 |
| + | *'''Generic name:''' teriprolizumab | ||
*'''Brand name:''' Tuoyi | *'''Brand name:''' Tuoyi | ||
| Line 24: | Line 27: | ||
[[Category:Non-small cell lung cancer, nonsquamous medications]] | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
[[Category:Non-small cell lung cancer, squamous medications]] | [[Category:Non-small cell lung cancer, squamous medications]] | ||
| − | [[Category:NMPA approved | + | [[Category:NMPA approved in 2018]] |
Revision as of 02:16, 11 August 2023
Mechanism of action
From the NCI Drug Dictionary: A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Bladder cancer
- Esophageal squamous cell carcinoma
- Melanoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, nonsquamous
- Non-small cell lung cancer, squamous
History of changes in NMPA indication
- 2018-12-17: Initial approval
Also known as
- Code names: JS-001, TAB-001
- Generic name: teriprolizumab
- Brand name: Tuoyi